Emcure Pharmaceuticals Ltd Q2 FY27 Earnings Call: Raises FY27 Revenue Growth Guidance Above 20%, Zuventus Turnaround Underway

Broad-Based Beat With Margin Expansion and a Guidance Raise

• Revenue of Rs.2,820 crore, +24.3% YoY and +9.3% QoQ — growth across all geographies; EBITDA (ex-other income) rose 31% YoY to Rs.575 crore with margin at 20.4%, up ~100 bps YoY and ~70 bps QoQ on productivity gains and operating leverage.
• PAT of Rs.325 crore, +29% YoY — PAT margin of 11.5% (+45 bps); PBT at Rs.446 crore (+31%) with an effective tax rate of 27%.
• Gross margin at 59.5%, up ~110 bps QoQ — driven by business and product mix; employee costs Rs.435 crore (+13%), other expenses Rs.669 crore (+20%) on higher sales and R&D spend.
• Other income fell to Rs.16 crore vs Rs.39 crore YoY — primarily on lower foreign exchange gains; finance cost at Rs.36 crore on increased borrowings to fund acquisition-related payouts.
• H1 FY 2026-2027 revenue of Rs.5,401 crore (+23.6%) — EBITDA Rs.1,083 crore (+28.6%, margin 20%, +~80 bps); PAT Rs.618 crore (+33%, margin 11.4%, +75 bps).
• Constant-currency growth of ~18.5% overall — currency impact was ~10% on the international top line; international CC growth ~24% (CFO Taj Sheikh).
• Net debt of Rs.1,317 crore as of September (Q2 FY27) — up Rs.263 crore vs March; H1 acquisition-related payouts totaled Rs.551 crore (Canada acquisition final payout, Genova minority stake, UK product portfolio); management remains committed to becoming net cash by end of FY28 (FY 2027-2028).

Second Straight Double-Digit Quarter; Zuventus Recovery Underway

• India grew 12% YoY to Rs.1,155 crore in Q2 FY 2026-2027 — second consecutive quarter of double-digit growth; organic growth improved to 10% from 6% in Q1 FY 2026-2027, led by women's health, cardiometabolic and CNS; management expects to build on this in H2 FY 2026-2027.
• Full-year FY 2026-2027 domestic growth expected closer to low teens — management expects to be at or above industry growth at the exit of FY27 (Piyush Nahar).
• Zuventus is roughly 25% of overall revenues — growth remains substantially below acute/IPM category growth (acknowledged to JP Morgan), though ex-Zuventus business is growing faster than the industry; attrition occurred predominantly in H2 FY 2025-2026, and H2 FY 2026-2027 is expected to be strong relative to H2 FY 2025-2026.
• Turnaround framework: stability → consolidation → acceleration — Satish Mehta said stability and consolidation are complete with acceleration underway; "the worst is behind us" on Zuventus.
• Povistra (obesity biologic) was the #4 brand in the API market in October 2026 — based on October 2026 numbers the rank should improve by at least 1 (Q3 FY 2026-2027); framed as a long-term investment requiring patience, with Emcure shaping the obesity market alongside Novo Nordisk.
• Domestic MR count at ~4,100–4,200 as of Q2 FY 2026-2027 — no new MR additions planned in the near term; productivity per rep up in Q2 vs the prior quarter; hospital channel contributes single digits (%) of domestic formulations, with focus on trade prescriptions.
• In-licensed products contribute a high-teens% of India sales — biosimilars ~10% of overall India sales; international biosimilars below 10%, limited to emerging markets only (as of Q2 FY 2026-2027).

International Now 59% of Revenue; Europe and ROW Lead

• International grew 34.5% YoY to Rs.1,665 crore (59% of revenue) — driven by base business expansion and new launches; Europe, Canada and ROW each contribute mid-teens-plus with hardly any product concentration within each market.
• Europe grew 36% YoY to Rs.604 crore — strong delivery across UK and continental Europe, led by the base portfolio, new launches and continued scale-up of liposomal amphotericin B; momentum expected to continue in H2 FY 2026-2027.
• Canada grew 24% YoY to Rs.431 crore — on base business growth and recent launches; further launches expected in H2 FY 2026-2027 with a strong pipeline being built.
• Rest of World grew 41% YoY to Rs.630 crore — ARV remained strong while non-ARV growth accelerated on new launches and portfolio expansion in Latin America, CIS, Asia and Africa.
• Europe and Canada growth is entirely organic — no acquisitions in the last 12 months; the Max acquisition was longer than 1.5 years ago and Cutimed in Canada was very tiny (Vik Thapar). Management did not quantify new-launch contribution; the analyst's ~10% assumption was not confirmed.
• Liposomal amphotericin B has penetrated ~50% of the European market — a few geographies recently approved and about 20 countries still pending entry; approvals recently received in Brazil and Colombia, with Mexico possibly "around the corner"; no Canada sales yet. Amphotericin B is well below 10% of international sales.
• Manufacturing risk diversified across 2 sites — CFO Taj Sheikh said most regulatory audits are recent and closed, with facilities expected to cater to markets without restriction over the next 18 to 24 months; UK approved at both sites, Europe expected on both in due course.

Lenacapavir, Semaglutide and Treprostinil Anchor the Launch Calendar

• Over 20 product approvals received in Q2 FY 2026-2027 — including liposomal amphotericin B in Brazil and Mexico, and bevacizumab for wet AMD in India.
• India's Subject Expert Committee issued a positive recommendation for lenacapavir injection for the PrEP indication — the company filed its dossier with WHO and USFDA for rest of world markets and looks forward to reviews progressing over the next few quarters; management believes Lenacapavir will be an important part of the ARV portfolio over the medium term and margin-accretive.
• Semaglutide filing in Canada likely within FY 2026-2027 — Emcure is awaiting semaglutide supplies for the Quebec launch with partner Dr. Reddy's, which has indicated November 2026 timing; Emcure is ready to launch upon receipt of supplies.
• Treprostinil expected to contribute significantly in Europe over the next 12 months — COO Samit Mehta described it as an attractive market with limited competition; not a very large volume product but very strong in value and margin.
• Non-ARV amphotericin B launches in ROW — batches for approved markets already under production; at least a couple of markets expected to launch during H2 FY 2026-2027.
• R&D investment of Rs.111 crore (~4% of revenue) in Q2 FY 2026-2027 — H1 ran at 4%; full-year FY 2026-2027 guidance maintained at 4-5% with the H2 step-up within that bracket, tilted toward international/complex opportunities.

Operating Leverage Intact, But Input Costs Eroded FX Gains

• Rising input costs offset currency gains in Q2 FY 2026-2027 — Vik Thapar said higher raw material, freight and insurance costs and longer transit times wiped out a big chunk (if not most) of favorable currency gains, leaving the gross margin impact "relatively muted"; no explicit H2 FY 2026-2027 gross margin outlook given.
• Margin improvement expected from operating leverage — SG&A growth expected slower than revenue growth with no meaningful incremental OpEx (capacity or marketing) flagged near term (no timeframe specified).
• Profitability hierarchy: India is the No. 1 vertical — though blended India margins include lower-standalone-margin in-licensing relationships with multinational partners; Europe, Canada and ROW non-ARV are very strong; ARV margins run below overall corporate margins.
• ARV mix at ~50% of ROW sales in Q2 FY 2026-2027 — vs ~67% in Q1 FY 2026-2027; management reaffirmed 50-55% ARV contribution for FY27 (FY 2026-2027); strong ARV order book supports continued revenue recognition in H2 FY 2026-2027.

FY27 Guidance Raised; FY28 Deliberately Left Unguided

• FY 2026-2027 revenue growth guidance raised to exceed 20% — vs mid-teens indicated earlier; driven by good domestic traction and international scale-up (especially ROW and Europe), with expected product approvals now received and ramping up.
• FY 2026-2027 EBITDA margin improvement now expected near the upper end of the 75-100 bps range — an upgrade from the earlier guidance band.
• Domestic acceleration of about 2x versus current numbers expected within FY 2026-2027 — management sees further acceleration in the domestic business in the fiscal year.
• No specific FY28 (FY 2027-2028) guidance yet — Vik Thapar said management feels bullish heading into H2 FY 2026-2027 and hopes momentum builds into FY28; mid-term growth expectations for each business vertical were reaffirmed.
• Management declined to guide on whether elevated IPM growth sustains into FY28 — citing geopolitical risk; Satish Mehta noted an Iran conflict flare-up pushing oil to $120-130/barrel could sharply slow growth, preferring a quarter-by-quarter assessment. He cited pharma's historical pattern of growing ~1.5x economic growth — 8% GDP growth implies 11-12% pharma growth — with the industry currently showing 14-15% growth.
• Obesity is contributing at least 4-5% to IPM — Satish Mehta noted Mounjaro is a ~Rs.1,300-1,400 crore brand running at >Rs.110 crore/month with semaglutide brands adding ~Rs.50-60 crore (~Rs.150 crore against an IPM of ~Rs.25,000 crore); flagged as a qualitative assessment requiring a deeper dive on sustainability.
• Zoentus amalgamation approved by the board on 12th October 2026 — Zoentus Healthcare and Emcure Pharmaceuticals (wholly owned subsidiaries) to merge into Emcure under the "One Emcure" vision; subject to necessary approvals including NCLT. Management stated H1 FY 2026-2027 performance reinforces confidence in achieving its 5-year goals (specific targets not quantified on the call).